Synageva completes enrollment in lysosomal acid lipase deficiency trial

Synageva BioPharma (GEVA) completes enrollment in a Phase 3 study of sebelipase alfa in LAL Deficiency.

Top-line results now expected in H2 2014. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs